摘要
目的观察支气管哮喘者接受孟鲁斯特钠联合布地奈德治疗的效果。方法选择笔者所在科室于2018年1—年10月期间收治的128例支气管哮喘患者,等分为(甲组、乙组)两组,分别接受布地奈德与布地奈德+孟鲁斯特钠治疗,比较两组疗效。结果乙组治疗总有效率为95.3%,明显高于甲组75.0%(48例)(P<0.01);治疗后,两组患者嗜酸性粒细胞计数均有所降低,乙组下降比甲组更为明显(P<0.05);两组患者在用药治疗期间均未出现明显不良反应。结论孟鲁斯特钠与布地奈德联合疗法用于支气管哮喘临床治疗,有助于降低嗜酸性粒细胞计数,疗效优良且具有较高安全性,值得推广。
Objective To observe the effect of treatment of bronchial asthma with montelukast sodium combined with budesonide.Methods A total of 128 patients with bronchial asthma who were admitted to the department from January to October 2018 were enrolled in the two groups(group A and group B).They were treated with budesonide and budesonide+montelukast.The efficacy of the two groups was compared.Results The total effective rate of treatment in group B was 95.3%,which was significantly higher than that in group A 75.0%(48 case)(P<0.01).After treatment,the eosinophil counts were decreased in both groups,and group B decreased more than group A(P<0.05);no significant adverse effects occurred during the treatment of the two groups of patients.Conclusion The combination of montelukast sodium and budesonide for the clinical treatment of bronchial asthma can help reduce eosinophil count,with excellent curative effect and high safety.It is worthy of promotion.
作者
李桂芳
LI Gui-fang(Pediatrics Department,Shenxian Maternal and Child Health Hospital,Shenxian,Shandong Province,252400 China)
出处
《系统医学》
2019年第5期116-117,123,共3页
Systems Medicine
关键词
支气管哮喘
孟鲁斯特钠
布地奈德
疗效观察
Bronchial asthma
Montelukast sodium
Budesonide
Therapeutic effect
